Carlsmed, Inc. CARL 深 沪
已收盘 10-31 16:00:00 美东时间
12.89
+0.180
+1.42%
华盛通- 最 高13.00
- 今 开12.91
- 成交量 7.27万股
- 最 低 12.25
- 昨 收 12.71
- 总市值 3.42亿
- 52周最高 16.20
- 市盈率 静 --
- 换手率 0.27%
- 52周最低 11.81
- 委 比 0.00%
- 总股本 2651.63万
- 历史最高 16.20
- 量 比 1.64
- 振 幅 5.90%
- 历史最低 11.81
- 每 手 1
- 风险率 0.75%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Carlsmed Secures $60 Million Credit Facility Amendment
Carlsmed, Inc. ( ($CARL) ) has shared an update. On October 29, 2025, Carlsmed,...
10-31 04:43
Biomea Fusion to Present Poster Presentations at ObesityWeek®2025
Biomea Fusion, Inc. will present preclinical data for BMF-650, an oral GLP-1 receptor agonist, and combination data for icovamenib with semaglutide at ObesityWeek® 2025. BMF-650 and icovamenib are part of Biomea’s portfolio targeting diabetes and obesity. The abstracts will be published in the Obesity journal supplement.
10-30 12:00
Biomea Fusion Announces 52-Week Phase II Data For Icovamenib In Type 2 Diabetes; Study Shows Sustained HbA1c Reduction And Favorable Safety Profile
Icovamenib showed a sustained treatment benefit at Week 52 (9 months past the end of treatment) in the severe insulin-deficient diabetes patient population taking one or more antihyperglycemic medications at baseline,
10-07 04:04
Carlsmed, Inc. Appoints Jennifer Kamocsay as Chief Legal Officer and Secretary
Carlsmed, Inc. has appointed Jenifer Kamocsay as its new Chief Legal Officer and Secretary. With over 20 years of experience in corporate legal roles within the life sciences and technology sectors, Kamocsay will oversee the company’s legal affairs, compliance, and corporate governance. Her expertise in securities law and corporate strategy is expected to support Carlsmed’s growth and upcoming cervical product launch. Kamocsay previously served a...
09-29 13:00
Carlsmed, Inc. Selected for Inclusion in Russell 2000® Index
Carlsmed, Inc. has been added to the Russell 2000 Index following its successful IPO in July 2025. The addition validates the company's differentiated business and growth in AI-enabled personalized spine surgery solutions. The Russell 2000 Index, tracking U.S. small-cap equities, represents about 10% of the Russell 3000 Index and is widely used by investors. Carlsmed aims to improve healthcare outcomes and reduce costs through its innovative tech...
09-22 13:00
高盛精选两大潜力股：AI营销平台Braze(BRZE.US)与医疗科技Carlsmed(CARL.US)获“买入“评级
Braze(BRZE.US)和Carlsmed(CARL.US)两只股票均获得高盛"买入"评级，且具有两位数上涨潜力。
09-15 09:20
Carlsmed® Reports Second Quarter 2025 Financial Results
Carlsmed reported Q2'25 revenue of $12.1 million, up 99% YoY, driven by increased adoption of its AI-enabled aprevo® technology in spine surgeries. Gross profit rose to $8.9 million, with a 73.4% margin, down slightly from last year due to production fees. Operating expenses climbed 47% to $15.4 million, reflecting increased R&D, sales, and marketing activities. Net loss widened to $6.8 million, while cash reserves stood at $33.5 million, bolster...
08-28 20:01
Earnings Scheduled For August 28, 2025
Companies Reporting Before The Bell • Li Auto (NASDAQ:LI) is expected to report...
08-28 16:32
Iovance Biotherapeutics Receives Health Canada NOC/c For Amtagvi
First T cell therapy for a solid tumor cancer and first treatment option approved in Canada for advanced melanoma after anti-PD-1 and targeted therapySAN CARLOS, Calif., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Iovance
08-19 04:24
Carlsmed's Personalized Spine Implants Get Significant Reimbursement Advantage
Carlsmed secures NTAP reimbursement and FDA support, while BofA projects strong revenue growth and assigns a Buy rating with a $16 target.
08-19 02:25
